# GLP-1 Drugs May Accelerate Muscle Loss in Older Adults
GLP-1 receptor agonist drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) help people lose weight, but researchers now warn these medications carry a hidden risk for adults over 65. Rapid weight loss from these drugs strips away muscle tissue along with fat, potentially triggering sarcopenia and frailty in aging bodies.
The concern centers on how these medications work. GLP-1 drugs suppress appetite aggressively, leading to significant calorie restriction. When older adults eat less overall, their bodies burn through muscle protein to meet energy needs. Unlike younger people who can rebuild muscle faster, seniors lose muscle mass at accelerated rates and struggle to regain it.
Sarcopenia, the age-related decline in muscle mass and strength, already affects roughly 10 percent of adults over 60. GLP-1 use appears to worsen this natural process. Frailty follows muscle loss, increasing fall risk, hospital stays, and loss of independence.
Experts recommend older adults taking GLP-1 drugs pursue targeted interventions. Resistance training and strength exercises become non-negotiable, not optional. Adequate protein intake (roughly 1.2 to 2 grams per kilogram of body weight daily for seniors) helps preserve lean tissue during weight loss. Regular check-ins with healthcare providers allow doctors to monitor muscle changes through grip strength tests or DEXA scans.
Parents with aging relatives considering GLP-1 therapy should discuss these risks openly. The drugs remain appropriate for many older adults with type 2 diabetes or obesity, but they require different management than standard weight loss approaches. Pairing medication with structured exercise programs and nutritional support protects against